Navigation Links
Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 and Phase 2 Trials Suggest High and Durable Response in Chronic Lymphocytic Leukemia
Date:12/8/2012

r 65 years old, after a median follow up of 20.3 months
  • 71 percent in patients with RR disease, including patients with HR CLL/SLL, after a median follow up of 15.7 months
    • The estimated PFS at 26 months is 96 percent for patients over 65 years of age with TN CLL and 75 percent for those with RR/HR disease
      • Estimated OS at 26 months is 96 percent in TN patients and 83 percent in patients with RR/HR disease

    Responses were independent of high-risk clinical or genetic features, such as a deletion of part of chromosome 17 (del17p).

    Most adverse events (AEs) were Grade 1 or 2 in severity, with the most common attributed to ibrutinib being diarrhea, fatigue, nausea and rash. Adverse hematologic events were relatively infrequent. In patients with cytopenia (low blood cell counts) at the beginning of the study, sustained improvements of platelet counts (78 percent) and hemoglobin (82 percent) were seen after treatment. There was no evidence of cumulative toxicity or long-term safety concerns.

    Oral presentation 187, The BTK inhibitor ibrutinib (PCI-32765) in combination with rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia (CLL) patients
    Jan A. Burger, M.D., Ph.D., MD Anderson Cancer Center, Houston, TX

    This presentation was based on findings from a Phase 2, single-center trial with 40 patients with HR CLL treated with 420 mg/day ibrutinib in combination with rituximab, a current standard CLL therapy. Patients with HR disease were previously treated and had one of the following characteristics: deletion of a part of chromosome 17 (del17p), which is associated with poorer treatment outcomes; a gene mutation called TP53; del11q, another partial chromosome deletion associated with poorer outcomes; or a short remission duration (less than three years) after first-line chemo-
    '/>"/>

    SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
    2. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
    3. Startling results in synthetic chemistry presented in Nature Chemistry
    4. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
    5. New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 Congress
    6. Top Contenders For the First Annual 2012 Fright Night Awards Presented By Cancer Bites Announced
    7. Promising Data Presented on GenVec Malaria Program
    8. Amgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting
    9. Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
    10. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    11. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2015)... Dallas, Texas (PRWEB) , ... July 30, 2015 , ... ... professional and in-depth study on the current state of the global Propanol market with ... are Sinopec, CNPC, BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal ...
    (Date:7/30/2015)... the globe, ISN improves the efficiency and effectiveness of contractor management systems. ISN,s online ... contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... in Dallas, TX , ISN has additional offices in Calgary ...
    (Date:7/30/2015)... ... July 30, 2015 , ... GEA's Pony™ NS2006L ... operation up to 1500 bar. The sanitary design gauge of the NS2006L is ... , The Pony™ NS2006L homogenizer is an ideal solution for the processing of ...
    (Date:7/29/2015)... Japan (Q2 2015: +14% CER / 20% of sales) ... in China , as well as solid contributions from Korea, ... Europe / Middle East / ... in Germany , Turkey and the ... 49% of sales) grew 11%, excluding U.S. HPV sales, on demand across all ...
    Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10
    ... in machining and tool making these days, consider the following: ... thin side of a dime, remove all the metal under ... surfaces of that same dime as thin as foil. , ... EDM instructor at Chippewa Valley Technical Colleges glass ...
    ... Dean Amhaus, the image-conscious president of Spirit of ... sitcom featuring two ditzy women who worked at a Milwaukee ... and S, in respect to Amhaus) is banned from his ... same. , ,Frank Langley of Pel-Freez , a biotech ...
    ... MADISON, Wis. - The Wisconsin Alumni Research Foundation ... Mentor Corporation a California-based publicly traded company (NYSE: MNT), ... marketing rights to the proprietary botulinum toxin technology developed ... pay WARF a royalty on sales of Botulinum toxin ...
    Cached Biology Technology:Powerful, Intricate Technology Taught in CVTCs New Tool and Die Program 2Powerful, Intricate Technology Taught in CVTCs New Tool and Die Program 3From Rustbelt to Techtown: Milwaukee is Building a New Image and a New Economic Reality. 2From Rustbelt to Techtown: Milwaukee is Building a New Image and a New Economic Reality. 3Mentor Licenses Botulinum From WARF and Plans Wisconsin Manufacturing Facility 2
    (Date:7/31/2015)... SHENZHEN , Kina, 31. juli 2015 ... ) bliver afholdt af BGI fra den 22. - 25. ... Konferencen fejrer sin 10-års fødselsdag i år. ... verdens mest indflydelsesrige årlige møder på ,omik,-feltet, og er ... forsamlinger. ICG-10 fokuserer på nylige gennembrud ...
    (Date:7/31/2015)... de 2015 BGI llevará a cabo la 10ª ... al 25 de octubre de 2015, en ... su décimo aniversario este año. Desde su inauguración en ... reuniones anuales más influyentes del mundo en los campos ... científicas más dinámicas, entusiastas y amenas. ICG-10 ...
    (Date:7/31/2015)... China , 31 de julho de 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) será realizada pela BGI de 22-25 ... . A conferência está celebrando seu ... em 2006, a ICG se tornou uma das reuniões ... um dos encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
    Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
    ... A new study from the Centers for Disease ... catheter-associated bloodstream infections caused by both methicillin-resistant and ... study, ,Methicillin-Resistant Staphylococcus aureus Central Line-Associated ... reported data from both the National Nosocomial Infection ...
    ... Institution of Oceanography at UC San Diego has provided ... Oceanography graduate student researcher Loren McClenachan accessed archival photographs ... a drastic decline of so-called "trophy fish" caught around ... paper published online in January and printed in an ...
    ... Lilly Singapore Centre for Drug Discovery (LSCDD), Singapore,s National ... Sciences (SICS), have teamed up to advance drug discovery ... is one of the institutions of SingHealth, the largest ... subsidiary of the US-based biopharmaceutical company, Eli Lilly and ...
    Cached Biology News:Press statement on new CDC MRSA study from SHEA president 2Historical photographs expose decline in Florida's reef fish, new Scripps study finds 2Historical photographs expose decline in Florida's reef fish, new Scripps study finds 3Singapore research organisations team up to advance drug discovery using brain tumor stem cells 2
    TMB Slow Kinetic One Component HRP Microwell Substrate, 1 L...
    Eppendorf tube holder, for Tube rack 175 x 12 mm, 100. Category: Chromatography Systems & Accessories, Systems....
    Pooled normal sreum with 0.1% sodium azide as preservative...
    Agarose, pulse field, 250 g. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1800 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
    Biology Products: